Education
- PhD, Health Policy (Economics Track), University of California at Berkeley, 2016
- MS, Economics, University of California at Berkeley, 2015
- MA, International Comparative Education, Stanford University, 2009
- BA, Economics and English, Peking University, China, 2008
Courses Taught
- HEOR 597: Graduate Seminar
- HEOR 598: HEOR Methodologies Seminar
Research Interests
- Decision-making in Aging
- Physician Behavior
- Policy Evaluation
- Experimental and Quasi-experimental Methods
Biography
Dr. Jing Li is a health economist with research interests in the economic, social and behavioral factors affecting individual decision-making in health and healthcare, for both providers and patients, and the impact of policies that leverage these factors to improve patient outcomes and healthcare market efficiency. Methodologically, she is interested in innovatively applying advanced experimental and econometric methods to addressing understudied questions in health economics and policy. Dr. Li’s current projects study experimentally measured social preferences (altruism) of physicians and their relationship with patient outcomes, healthcare and financial decision-making for older adults with cognitive impairments including Alzheimer’s disease and related dementias, and conflicts of interest in physician drug prescribing.
Selected Publications
https://www.ncbi.nlm.nih.gov/myncbi/jing.li.13/bibliography/public/
Education:
- PhD, Economics, McGill University
Research Interests:
- Health policy and healthy aging
- Chronic disease management
- Alzheimer’s disease and dementia prevention and management
- Disparities in utilization and effectiveness of pharmaceutical therapies
- Pharmacist regulations
- Health insurance design
Courses Taught:
Biography:
Douglas Barthold is a health economist and Associate Professor at the University of Washington, specializing in the intersection of health policies, healthcare utilization, and health outcomes, with particular focus on aging, dementia, and prescription drug policy. He is faculty at the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, serves as Co-Director of the Program in Health Economics and Outcomes Research Methodology (PHEnOM), and is a Board Member of the Washington State Prescription Drug Affordability Board. His research explores how health insurance design and prescription drug costs impact management of chronic diseases, including mid-life risk factors for dementia. Barthold holds a Ph.D. in Economics from McGill University and previously did postdoctoral research at the Schaeffer Center for Health Policy and Economics at the University of Southern California.
Selected Publications:
https://sites.google.com/site/douglasbarthold/peer-reviewed-publications
Positions
Professor of Pharmacy, School of Pharmacy, Professor of Health Services, School of Public Health, University of Washington
Education
- BSc.Pharm 1983 Oregon State University, College of Pharmacy
- M.Sc. 1986 University of Texas, College of Pharmacy (Administrative and Economic Sciences)
- Ph.D. 1992 University of California, Berkeley (Health Economics and Policy)
Research Interests
- Pharmaceutical policy
- Economic evaluation of pharmaceuticals
- Global health technology assessment
- Medical decision making
Courses Taught
- HECON 530 – Practice of Healthcare Technology Assessment in a Global Environment
- HEOR 545 – Topics in Pharmaceutical Policy
- PHRMCY 515 – Population Health and Pharmacy Management
Biography
Sean D. Sullivan, BScPharm, MSc, PhD, is a Professor, School of Pharmacy and Visiting Professor, London School of Economics and Political Science. He holds a joint appointment as Professor of Health Services, School of Public Health. Dr. Sullivan was Dean of the School of Pharmacy from 2014 to 2022.
He completed training in pharmacy at Oregon State University in 1983, obtained a master’s degree at the University of Texas in 1986 and a PhD in health economics and policy at the University of California, Berkeley in 1992.
Dr. Sullivan has authored more than 450 articles, book chapters and reports. In many of these, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include health technology assessment, medical decision-making, and economic evaluation of medical technology, including pharmaceuticals. He is past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) Executive Committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision making.
Dr. Sullivan was a member of the Medicare Evidence Development and Coverage Advisory Committee, Chair of the Regence Blue Shield and Premera Blue Cross P/T Committee, and Chair of the Premera Blue Cross Value Assessment Committee. He was awarded the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy (AMCP), and the 2015 APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award. In 2020, he was elected to the National Academy of Medicine and in 2022 was elected Fellow, American Association for the Advancement of Science (AAAS).
Selected Publications
- Cousin EM, Sullivan SD, Gabriel N, Hansen RN, Hernandez I. Drugs Anticipated to Be Selected for Medicare Price Negotiation in 2025 for Implementation in 2027. J Manag Care Spec 2024 Nov;30(11):1203-1210. doi: 10.18553/jmcp.2024.24167.
- Sullivan SD, Wouters OJ, Cousin EM, Kirihennedige A, Hernandez I. Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform Medicare Drug Price Negotiation. Value in Health 2024 Oct;27(10):1348-1357. doi: 10.1016/j.jval.2024.08.001.
- Hernandez I, Wouters OJ, Cousin EM, Kirihennedige A, Sullivan SD. Interpreting the First Round of Maximum Fair Prices Negotiated by Medicare for Drugs. Health Affairs Forefront 2024 September 3, 2024 10.1377/forefront.20240830.863408
- Wouters OJ, Sullivan SD, Cousin EM, Gabriel N, Papanicolas I, Hernandez I. Drug Prices Negotiated by Medicare vs US Net Prices and Prices in Other Countries. JAMA 2025 Jan 7;333(1):85-87. doi: 10.1001/jama.2024.22582.
- Sullivan SD, Chaturvedi S, Gautam P, Arnaud A. Cost effectiveness of caplacizumab in Immune thrombotic thrombocytopenic purpura in the US. J Manag Care Spec 2024 Dec 23:1-12. doi: 10.18553/jmcp.2025.24271.
- Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD. Overpayment for Generic Drugs under Medicare Part D: Consequences on Patient Out-of-Pocket Costs. JAMA Health Forum 2025; 6(2):e250012. doi:10.1001/jamahealthforum.2025.0012
- Hernandez I, Gabriel N, Japinga M, Pathak Y, Hansen RN, Sullivan SD, Fendrick AM. Projected Out of Pocket Savings of the Medicare Part D Two Dollar Drug List. JAMA 2025 March 24 On-line doi:10.1001/jama.2025.2028
- Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD. The Price Effects of Biosimilars in the US. Value in Health 2025. https://doi.org/10.1016/j.jval.2025.02.008
- Sullivan SD, Grueger J, Sullivan AP, Ramsey SD. The Consequences of Pharmaceutical Tariffs in the US. JMCP In press, May, 2025
- Sun, L, Veenstra DL, Brufsky A, Pluard T, Sandin R, Stergiopoulos S, Liu J, Williams T, Sullivan SD. First Line CDK4/6 Inhibitors in Combination with Aromatase Inhibitors for HR+/HER2- Metastatic Breast Cancer: Real World Outcomes and Costs in a Medicare Population. J Manag Care Spec Pharm in press, 2025
Education
- PharmD, University of Michigan
- MS in Epidemiology, University of Washington
Courses Taught
- PHARM 562: Pharmacotherapeutics V
- PHARM 550: Seminar in Geriatrics
Research Interests
- Medication safety in older adults
- Deprescribing
- Medication use and risk for falls, fractures, dementia
Biography
Dr. Gray has been a faculty member in the UW Department of Pharmacy since 1992. She is an investigator on numerous federally funded research grants and is author of more than sixty peer-reviewed publications. Earlier in her career, she received an American Association of Colleges of Pharmacy New Investigator Award and a Career Development Award from the National Institute on Aging. She serves on the editorial board for the “Annals of Pharmacotherapy”, “Journal of the American Geriatrics Society” and “Research in Gerontological Nursing”.
Gray has served as a consultant pharmacist for Providence Elderplace. Previously, she completed a two-year fellowship in geriatrics at the University of North Carolina at Chapel Hill and a clinical pharmacy residency at Thomas Jefferson University Hospital in Philadelphia. She has served on various committees of pharmacy and geriatric professional organizations.
Selected Publications
- Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015:2175(3):401-7.
- Gray SL, Dublin S, Yu O, Walker R, Anderson M, Crane P, Larson E. Benzodiazepine use and risk of incident dementia or cognitive decline. BMJ. 2016;352:i90.
- Gray SL, Walker RL, Dublin S, Yu O, Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk. J Am Geriatr Soc. 2018;66(2):247-253.
- Gray SL, Anderson ML, Hanlon JT, Dublin S, Walker R, Hubbard, RA, Yu O, Montine T, Sonnen J, Keene CD, Crane PK, Larson EB. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. J Alzheimers Dis 2018;65(2):607-616.
Education
- PhD, Public Policy (Health Economics), University of Chicago, 2004
- MS, Biostatistics, UNC-Chapel Hill, 1999
- MS, Industrial Pharmacy, University of Toledo, 1997
- BS, Pharmaceutical Technology, Jadavpur University India
Courses Taught
- Welfare Economics foundations for cost-effectiveness analysis (HSERV 583, ’11 & ‘12) – 1.5 hour sessions
- Understanding the role of uncertainty in decision models (HSERV 583, ’13 & ‘14) – 1.5 hour sessions
- Quantitative methods for valuing information in health care (HSERV 584, ‘11) – 1.5 hour sessions
- Introduction to comparative effectiveness methods (HSERV 523, ’11; HSERV 513 & HSERV 592, ’12) – 1.5 hour sessions
- Instrumental variable methods (HSERV 523, ‘11) – 1.5 hour session
- Financing healthcare (HuBio 555, ’13, ‘14) – 1.5 hour session to 250 2nd year medical students
- Quantile regression methods (HSERV 525, ’11, HSERV 523, ‘12) – 1.5 hour sessions
- Variations in healthcare spending: Observations & Implications (PHARM 568, ’14 -‘16) – 1.5 hour sessions
- Causal inference in observational studies (HSERV 525), Spring 2013 -2019- Ten 3 hour sessions.
Research Interests
- comparative and cost-effectiveness analyses
- causal inference methods
- program evaluation, and outcomes research
Biography
Anirban Basu, PhD, MS, is a health economist and a statistician who specializes in research on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research. He directs The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington, Seattle, with appointments in the departments of Pharmacy, Health Services, and Economics at the university. He is a Faculty Research Fellow at the National Bureau of Economic Research, and a Fellow of the American Statistical Association. He was one of the panelists for the Second Panel on the Cost-Effectiveness Analysis in Health and Medicine. He studies heterogeneity in clinical and economic outcomes, micro behavior with respect to heterogeneous information, and the value of individualized care. He teaches topics in health economics, decision analysis, cost-effectiveness analysis, and health services research methods. He received his PhD in Public Policy (Health Economics Specialization) from The University of Chicago and an MS in Biostatistics from the University of North Carolina at Chapel Hill. http://faculty.washington.edu/basua/
Selected Publications
https://scholar.google.com/citations?user=AR72duAAAAAJ&hl=en
Dr. Bansal is an Associate Professor and the Edwin S.H. Leong Chair in Data Science for Child Health at the Institute of Health Policy, Management and Evaluation, University of Toronto and The Hospital for Sick Children. Prior to joining the University of Toronto in September 2025, Dr. Bansal served on the faculty at The CHOICE Institute and Department of Pharmacy for 12 years. Dr. Bansal’s research focuses on sequential decision-making using longitudinal data, prediction modeling, decision theoretic methods including value of information analysis, and comparative effectiveness and outcomes research using large healthcare claims databases and EHR data. She is the PI of a study to develop methods for cost-effective personalized risk-adaptive surveillance in cancer.
Education
- Ph.D. Biostatistics, University of Washington, Seattle, WA
- M.S. Biostatistics, University of Washington, Seattle, WA
- B.Math. Honors Computer Science: Bioinformatics Option, University of Waterloo, Waterloo, Ontario
Courses Taught
- BIOST 512: Medical Biometry II
- HEOR 552 Application of Machine Learning in Health Economics and Outcomes Research
Research Interests
- Clinical decision sciences
- Development and evaluation of prediction models
- Comparative effectiveness and outcomes research
Selected Publications
https://www.ncbi.nlm.nih.gov/myncbi/aasthaa.bansal.1/bibliography/public/